Development of a prognostic model for glioblastoma multiforme based on the expression levels of efferocytosis-related genes
This study aimed to develop an efferocytosis-related prognostic model for GBM. The bioinformatic methods were utilized to analyze the transcriptomic data of GBM and normal samples. Clinical and RNA-seq data were sourced from TCGA database comprising 167 tumor samples and 5 normal samples, and 167 tumor samples for which survival information was available. Transcriptomic data of 1034 normal samples were collected from the Genotype-Tissue Expression (GTEx) database as a control sample supplement to the TCGA database. In the end, 167 tumor samples and 1039 normal samples were obtained for transcriptome analysis. Efferocytosis...
Source: Aging - December 30, 2023 Category: Biomedical Science Authors: Wenzhe Xu Lihui Han Pengfei Zhu Yufeng Cheng Xuan Chen Source Type: research
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13156. Online ahead of print.ABSTRACTDacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature revie...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Viktoria Ryd én Ali Inan El-Naggar Anthoula Koliadi Cecilia Olsson Ladjevardi Evangelos Digkas Antonios Valachis Gustav J Ullenhag Source Type: research
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13156. Online ahead of print.ABSTRACTDacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature revie...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Viktoria Ryd én Ali Inan El-Naggar Anthoula Koliadi Cecilia Olsson Ladjevardi Evangelos Digkas Antonios Valachis Gustav J Ullenhag Source Type: research
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Pigment Cell Melanoma Res. 2023 Dec 29. doi: 10.1111/pcmr.13156. Online ahead of print.ABSTRACTDacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line treatment, immune checkpoint inhibitors (CPIs) might shape the tumor and the tumor microenvironment, possibly affecting the response to subsequent therapies. The aim of this study was to investigate the treatment effect of DTIC/TMZ in MM patients after CPI therapy in a consecutive patient cohort and through systematic literature revie...
Source: Pigment Cell and Melanoma Research - December 29, 2023 Category: Cytology Authors: Viktoria Ryd én Ali Inan El-Naggar Anthoula Koliadi Cecilia Olsson Ladjevardi Evangelos Digkas Antonios Valachis Gustav J Ullenhag Source Type: research
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
ConclusionFor glioblastoma patients, extending post-radiation temozolomide from 6 to 12 months is well tolerated but does not improve 6mPFS. We could not identify any subset that benefitted from extended treatment. Six months should remain standard-of-care. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 28, 2023 Category: Cancer & Oncology Source Type: research
Unveiling the Influence of Tumor Microenvironment and Spatial Heterogeneity on Temozolomide Resistance in Glioblastoma Using an Advanced Human In Vitro Model of the Blood ‐Brain Barrier and Glioblastoma (Small 52/2023)
Microfluidic ModelsIn article number2302280, Andrea Pavesi and co-workers develop an in vitro 3D glioblastoma model, that incorporates a perfusable blood-brain barrier. The model recapitulates key features of clinical disease, such as a diffusive infiltrating tumor front and tumor-associated dysregulation of vascular permeability. The authors further demonstrate the compatibility with next-generation ultra-sensitive mass spectrometry to explore proteins involved in tumorigenesis and drug resistance. (Source: Small)
Source: Small - December 27, 2023 Category: Nanotechnology Authors: Maxine SY Lam,
Joey JY Aw,
Damien Tan,
Ragavi Vijayakumar,
Hui Yi Grace Lim,
Swathi Yada,
Qing You Pang,
Nick Barker,
Carol Tang,
Beng Ti Ang,
Radoslaw M. Sobota,
Andrea Pavesi Tags: Frontispiece Source Type: research
Cancers, Vol. 16, Pages 102: Progress in Glioma Stem Cell Research
gli Liu
Glioblastoma multiforme (GBM) represents a diverse spectrum of primary tumors notorious for their resistance to established therapeutic modalities. Despite aggressive interventions like surgery, radiation, and chemotherapy, these tumors, due to factors such as the blood–brain barrier, tumor heterogeneity, glioma stem cells (GSCs), drug efflux pumps, and DNA damage repair mechanisms, persist beyond complete isolation, resulting in dismal outcomes for glioma patients. Presently, the standard initial approach comprises surgical excision followed by concurrent chemotherapy, where temozolomide (TMZ) se...
Source: Cancers - December 24, 2023 Category: Cancer & Oncology Authors: Vanajothi Ramar Shanchun Guo BreAnna Hudson Mingli Liu Tags: Review Source Type: research
Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity
CONCLUSIONS: Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.PMID:38130902 | PMC:PMC10733660 | DOI:10.1093/noajnl/vdad152 (Source: Adv Data)
Source: Adv Data - December 22, 2023 Category: Epidemiology Authors: Maikel Verduin Linde Hoosemans Maxime Vanmechelen Mike van Heumen Jolanda A F Piepers Galuh Astuti Linda Ackermans Olaf E M G Schijns Kim R Kampen Vivianne C G Tjan-Heijnen Buys A de Barbanson Alida A Postma Danielle B P Eekers Martijn P G Broen Jan Becke Source Type: research
Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors
CONCLUSIONS: Patients with advanced or metastatic MPNST often succumb to their disease despite multiple lines of therapy. These data may be used as comparative information in decision-making for future patients and clinical trials.PMID:38130899 | PMC:PMC10733661 | DOI:10.1093/noajnl/vdad156 (Source: Adv Data)
Source: Adv Data - December 22, 2023 Category: Epidemiology Authors: Lindy Zhang Kathryn M Lemberg Ana Calizo Ravi Varadhan Alan H Siegel Christian F Meyer Jaishri O Blakeley Christine A Pratilas Source Type: research
Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity
CONCLUSIONS: Overall, these findings demonstrate the robustness of PGOs in retaining the genetic and phenotypic heterogeneity in culture and the application of measuring clinically relevant drug responses. These data show that PGOs have the potential to be further developed into avatars for personalized adaptive treatment selection and actionable drug target discovery and as a platform to study GBM biology.PMID:38130902 | PMC:PMC10733660 | DOI:10.1093/noajnl/vdad152 (Source: Adv Data)
Source: Adv Data - December 22, 2023 Category: Epidemiology Authors: Maikel Verduin Linde Hoosemans Maxime Vanmechelen Mike van Heumen Jolanda A F Piepers Galuh Astuti Linda Ackermans Olaf E M G Schijns Kim R Kampen Vivianne C G Tjan-Heijnen Buys A de Barbanson Alida A Postma Danielle B P Eekers Martijn P G Broen Jan Becke Source Type: research
Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors
CONCLUSIONS: Patients with advanced or metastatic MPNST often succumb to their disease despite multiple lines of therapy. These data may be used as comparative information in decision-making for future patients and clinical trials.PMID:38130899 | PMC:PMC10733661 | DOI:10.1093/noajnl/vdad156 (Source: Adv Data)
Source: Adv Data - December 22, 2023 Category: Epidemiology Authors: Lindy Zhang Kathryn M Lemberg Ana Calizo Ravi Varadhan Alan H Siegel Christian F Meyer Jaishri O Blakeley Christine A Pratilas Source Type: research
Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or durvalumab. Although SCLC first-line therapy often leads to rapid responses, treatment becomes more challenging at progression, particularly for those with a chemotherapy-free interval (CTFI) of ≤6 months. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for SCLC no longer specify treatment recommendations in this setting, but options approved by the US Food and Drug...
Source: Frontiers in Oncology - December 22, 2023 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 64: Treatment Outcomes after Dose-Escalated Moderately Hypofractionated Radiotherapy for Frail Patients with High-Grade Glioma
Chong
Won Jae Lee
For high-grade glioma (HGG) patients with old age or poor performance status, hypofractionated radiotherapy (hypoRT) in 10–15 fractions is recommended. Also, limited data exist on the impact of salvage treatment after progression in frail patients. We retrospectively analyzed the outcomes of dose-escalated hypoRT in 40 frail HGG patients who were treated with hypoRT between 2013 and 2021. With a median biologically effective dose of 71.7 Gy, a total dose of 56 Gy in 20 fractions was the most frequently used regimen (53.7%). The median age and Karnofsky Performance Status of patients we...
Source: Cancers - December 21, 2023 Category: Cancer & Oncology Authors: Nalee Kim Hyunju Shin Do Hoon Lim Do-Hyun Nam Jung-Il Lee Ho Jun Seol Doo-Sik Kong Jung Won Choi Kyuha Chong Won Jae Lee Tags: Article Source Type: research
MGMT promoter methylation in 1p19q-intact gliomas
ConclusionsThis ancillary analysis supports conclusions from the CATNON trial for adjuvant TMZ as standard-of-care for anaplastic astrocytomas (IDH-mutant and 1p19q-intact), irrespective ofMGMT status. Determining the optimal strategy for diffuse gliomas that are IDH-wildtype will be particularly important.MGMT promoter methylation should be considered as a stratification factor in future clinical trials for these patients. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - December 20, 2023 Category: Cancer & Oncology Source Type: research
Cancers, Vol. 16, Pages 9: KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway
ide Kondo
Kojiro Wada
Koichi Ichimura
Arata Tomiyama
Here, we investigated the detailed molecular oncogenic mechanisms of a novel receptor tyrosine kinase (RTK) fusion, KLC1-ROS1, with an adapter molecule, KLC1, and an RTK, ROS1, discovered in pediatric glioma, and we explored a novel therapeutic target for glioma that possesses oncogenic RTK fusion. When wild-type ROS1 and KLC1-ROS1 fusions were stably expressed in the human glioma cell lines A172 and U343MG, immunoblotting revealed that KLC1-ROS1 fusion specifically activated the JAK2-STAT3 pathway, a major RTK downstream signaling pathway, when compared with w...
Source: Cancers - December 19, 2023 Category: Cancer & Oncology Authors: Takashi Fujii Yoshiko Nakano Daichi Hagita Nobuyuki Onishi Arumu Endo Masaya Nakagawa Toru Yoshiura Yohei Otsuka Satoru Takeuchi Mario Suzuki Yuzaburo Shimizu Terushige Toyooka Yuko Matsushita Yuko Hibiya Satoshi Tomura Akihide Kondo Kojiro Wada Koichi Ic Tags: Article Source Type: research
